tiprankstipranks
Cue Biopharma price target lowered to $8 from $9 at Stifel
The Fly

Cue Biopharma price target lowered to $8 from $9 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Cue Biopharma to $8 from $9 and keeps a Buy rating on the shares. Stifel anticipates incremental/updated FY23 data from the dose-expansion portion of its Phase 1 trial evaluating CUE-101 in combination with pembrolizumab in 1L HPV+ SCCHN patients to build on "encouraging" preliminary results to date. Furthermore, FY23 dose-escalation data for CUE-102 remains an "interesting option" at these levels and any unambiguous evidence of the single-agent activity could potentially inflect the stock, Stifel tells investors.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CUE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles